Colorado Springs, Colo.-based Spectranetics Corp., a single-use medical device manufacturer, has announced its clinical trial plans related to the treatment of in-stent restenosis in arteries above the knee. Currently, there are no devices cleared or approved by the FDA to treat in-stent restenosis. The company has planned to initiate a multicenter randomized trial in the US to compare laser ablation followed by adjunctive balloon angioplasty with balloon angioplasty alone.